cladribine Treatment for Multiple Sclerosis FDA Accepts File for Cladribine Tablets as Potential Treatment for Relapsing Forms of Multiple Sclerosis ROCKLAND, Mass., July 30, 2018 /PRNewswire/ — EMD Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, Germany, in the U.S. and Canada, today announced that a resubmission of the New Drug Application (NDA) for cladribine […]Continue Reading ...
After a setback a number of years in the past, the Ecu Fee licensed cladribine (Mavenclad) 10-mg drugs for treating extremely lively relapsing a couple of sclerosis, drugmaker Merck KGaA introduced. Approval follows effects from segment III trials — together with CLARITY and ORACLE MS — that confirmed the short-course oral remedy had an have […]Continue Reading ...
Would possibly three, 2017 Merck introduced the presentation of latest analyses of efficacy and protection knowledge for investigational Cladribine Pills in poster shows on the Annual Assembly of the American Academy of Neurology (AAN), that happened April 22 – 28, 2017, in Boston, Massachusetts. The findings from a retrospective subgroup research of the Section III […]Continue Reading ...
Might three, 2017 Merck introduced the presentation of recent analyses of efficacy and protection information for investigational Cladribine Capsules in poster displays on the Annual Assembly of the American Academy of Neurology (AAN), that happened April 22 – 28, 2017, in Boston, Massachusetts. The findings from a retrospective subgroup research of the Segment III CLARITY […]Continue Reading ...
- Evoke Pharma Submits Response to FDA Review Letter for Gimoti NDA
- Tracking HIV’s ever-evolving genome in effort to prioritize public health resources
- Scientists grow most sophisticated brain organoid to date
- ADHD drug raising risk of psychosis
- FDA approves brexanolone, first drug developed to treat postpartum depression
- Gruesome cat and dog experiments by the USDA exposed
- Ball pits used in children’s physical therapy may contribute to germ transmission
- Long-term use of inexpensive weight-loss drug may be safe and effective
- FDA Approves Sunosi (solriamfetol) for Excessive Daytime Sleepiness Associated with Narcolepsy or Obstructive Sleep Apnea
- Anti-Müllerian Hormone Test: MedlinePlus Lab Test Information
- Finding the right exercise, diet aids for HIV patients
- Health Plans For State Employees Use Medicare’s Hammer On Hospital Bills
- Researchers develop new tool for imaging large groups of neurons in living animals
- Certain bacteria and immune factors in vagina may cause or protect against preterm birth
- Novel breath test could pave new way to non-invasively measure gut health
- Pharmaceutical and personal care products may result in new contaminants in waterways
- ACC: Catheter Ablation Does Not Cut Mortality, Stroke in A-Fib
- Wiedemann-Rautenstrauch syndrome – Genetics Home Reference
- Health insurance is not assurance of healthcare
- Supporting “curiosity-driven research” at the Discovery Innovation Awards